ACTRN12614000384651已完成1 期
A placebo controlled double-blind cross over study in participants suffering a functional bowel disorder comparing the effects of supplementation with butyrylated high amylose starch (HAMSB) with placebo starch (low amylose maize starch, LAMS) on overall gastrointestinal symptoms.
CSIRO Health and Biosecurity0 个研究点目标入组 40 人开始时间: 2014年4月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 20 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Medically diagnosed with a functional bowel disorder
排除标准
- •1. Constipation is only symptom
- •2. Intolerant to high fibre products
- •3. Celiac disease
- •4. Previous abdominal surgery
- •5. Diabetes
- •6. Use of antibiotics for 2 months prior to the commencement of the trial
- •7. Using anti-diarrhoeal drugs
- •8. Pregnant or breast feeding, or intending to become pregnant during the study
研究者
相似试验
进行中（未招募）
1 期
A double-blind placebo controlled cross-over study to determine if 1.5 and 3mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating sleep onset. - N/AEUCTR2004-003939-32-GBAlliance Pharmaceuticals Ltd80
进行中（未招募）
不适用
A double blind placebo controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention deficit hyperactivity disorder - Effects of atomoxetine on attention and driving in adult ADHDThe effects of atomoxetine on driving performance, attention and response inbihition are studied in adult patients with attention-deficit hyperactivity disorderEUCTR2007-001855-20-NLFaculty of Social Sciences, Utrecht University30
已完成
2 期
The use of APL510 to improve the length of day time sleep in subjects working permanent night-shiftsMental and Behavioural DisordersNonorganic sleep disordersInsomniaISRCTN15733268Alliance Pharmaceuticals Ltd (UK)44
已完成
2 期
1.5 versus 3.0 mg APL510 to normalise sleep patterns in elderly subjects with insomniaMental and Behavioural DisordersNonorganic sleep disordersInsomniaISRCTN82088636Alliance Pharmaceuticals Ltd (UK)80
进行中（未招募）
1 期
A double-blind placebo-controlled cross-over study to determine if melatonin can improve the length of day time sleep in subjects with transient misalignment of the sleep-wake cycle as a result of working permanent night shifts.Transient misalignment of the sleep-wake cycle as a result of working night shifts (insomnia in night shift workers)EUCTR2005-000120-17-GBAlliance Pharmaceuticals Ltd60